Kindred Biosciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Kindred Biosciences Inc announces pricing of IPO
Kindred Biosciences Inc:Says pricing of its initial public offering of 7,500,000 shares of its common stock at an initial public offering price of $7.00 per share for a total offering amount of $52,500,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by Kindred Bio.Says it has granted to the underwriters a 30-day option to purchase an additional 1,125,000 shares of its common stock at the initial public offering price.Says all of the shares are being offered by Kindred Bio.Says the shares are expected to begin trading under the ticker 'KIN' on the NASDAQ Capital Market on Dec.12.Says BMO Capital Markets and Guggenheim Securities are acting as book-running managers for the offering and Roth Capital Partners is acting as co-manager for the offering.
Latest Developments for Kindred Biosciences Inc
Latest Key Developments in Biotechnology
- FDA designates Regado Biosciences Inc's REG1 in PCI as a fast track development program
- Omeros Corporation announces positive OMS721 Data in Serum from patients with aHUS
- Amarantus BioScience Holdings Inc closes warrant solicitation and enters into $20 mln purchase agreement with Lincoln Park Capital Fund, LLC
- Neurovive Pharmaceutical to evaluate IPO of subsidiary in Taiwan
- Share this
- Digg this